Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients
Abstract Background The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first‐line immunotherapy and chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effecti...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70175 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206521382830080 |
|---|---|
| author | Xiaoli Mu Yixin Zhou Qing Liu Jiantao Wang Feng Xu Feng Luo Ke Wang Lu Li Panwen Tian Yalun Li Jiewei Liu Yan Zhang Jiyan Liu Yan Li |
| author_facet | Xiaoli Mu Yixin Zhou Qing Liu Jiantao Wang Feng Xu Feng Luo Ke Wang Lu Li Panwen Tian Yalun Li Jiewei Liu Yan Zhang Jiyan Liu Yan Li |
| author_sort | Xiaoli Mu |
| collection | DOAJ |
| description | Abstract Background The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first‐line immunotherapy and chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effectiveness and safety of tRT in combination with first‐line immunotherapy and chemotherapy. Methods Our retrospective study included patients with ES‐SCLC, treated at the West China Hospital between January 2019 and December 2022. They received first‐line immunotherapy and chemotherapy and were categorized into two cohorts based on the administration of tRT. The primary outcomes were overall survival (OS) and progression‐free survival (PFS). Cox regression analysis was utilized to identify potential independent predictors of prognosis and to compare the treatment outcomes across various patient subgroups. Treatment‐related toxicities across both cohorts were compared using the Chi‐squared test. Results A total of 99patients were eligible for the study, out of which 55 received tRT. The medianduration of follow‐up was 39 months. Remarkably, patients who received tRTdemonstrated superior OS and PFS in comparison to those who did not (P < 0.05). Subgroup analysis further confirmed these findings. Multivariate analysisidentified treatment group and liver metastasis as independent prognosticfactors (P < 0.05). The incidence of grade 3‐4 adverse events showed nostatistically significant difference between the two cohorts. Conclusions Thus, weconfirmed that the addition of tRT to the conventional regimen of first‐linechemotherapy and immunotherapy yields better survival outcomes without asignificant increase in toxicity. |
| format | Article |
| id | doaj-art-ddb9d6bc634c47bbaef54d5260f49207 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-ddb9d6bc634c47bbaef54d5260f492072025-02-07T09:08:08ZengWileyCancer Medicine2045-76342024-09-011317n/an/a10.1002/cam4.70175Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patientsXiaoli Mu0Yixin Zhou1Qing Liu2Jiantao Wang3Feng Xu4Feng Luo5Ke Wang6Lu Li7Panwen Tian8Yalun Li9Jiewei Liu10Yan Zhang11Jiyan Liu12Yan Li13The Department of Biotherapy, Cancer Center West China Hospital, Sichuan University Chengdu Sichuan ChinaThe Department of Biotherapy, Cancer Center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaThe Department of Biotherapy, Cancer Center West China Hospital, Sichuan University Chengdu Sichuan ChinaLung cancer center West China Hospital, Sichuan University Chengdu Sichuan ChinaAbstract Background The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first‐line immunotherapy and chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effectiveness and safety of tRT in combination with first‐line immunotherapy and chemotherapy. Methods Our retrospective study included patients with ES‐SCLC, treated at the West China Hospital between January 2019 and December 2022. They received first‐line immunotherapy and chemotherapy and were categorized into two cohorts based on the administration of tRT. The primary outcomes were overall survival (OS) and progression‐free survival (PFS). Cox regression analysis was utilized to identify potential independent predictors of prognosis and to compare the treatment outcomes across various patient subgroups. Treatment‐related toxicities across both cohorts were compared using the Chi‐squared test. Results A total of 99patients were eligible for the study, out of which 55 received tRT. The medianduration of follow‐up was 39 months. Remarkably, patients who received tRTdemonstrated superior OS and PFS in comparison to those who did not (P < 0.05). Subgroup analysis further confirmed these findings. Multivariate analysisidentified treatment group and liver metastasis as independent prognosticfactors (P < 0.05). The incidence of grade 3‐4 adverse events showed nostatistically significant difference between the two cohorts. Conclusions Thus, weconfirmed that the addition of tRT to the conventional regimen of first‐linechemotherapy and immunotherapy yields better survival outcomes without asignificant increase in toxicity.https://doi.org/10.1002/cam4.70175ChemotherapyExtensive‐stage small cell lung cancerImmunotherapySurvival outcomesThoracic radiotherapy |
| spellingShingle | Xiaoli Mu Yixin Zhou Qing Liu Jiantao Wang Feng Xu Feng Luo Ke Wang Lu Li Panwen Tian Yalun Li Jiewei Liu Yan Zhang Jiyan Liu Yan Li Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients Cancer Medicine Chemotherapy Extensive‐stage small cell lung cancer Immunotherapy Survival outcomes Thoracic radiotherapy |
| title | Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients |
| title_full | Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients |
| title_fullStr | Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients |
| title_full_unstemmed | Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients |
| title_short | Impact of thoracic radiotherapy on first‐line treatment outcomes in ES‐SCLC patients |
| title_sort | impact of thoracic radiotherapy on first line treatment outcomes in es sclc patients |
| topic | Chemotherapy Extensive‐stage small cell lung cancer Immunotherapy Survival outcomes Thoracic radiotherapy |
| url | https://doi.org/10.1002/cam4.70175 |
| work_keys_str_mv | AT xiaolimu impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT yixinzhou impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT qingliu impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT jiantaowang impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT fengxu impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT fengluo impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT kewang impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT luli impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT panwentian impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT yalunli impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT jieweiliu impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT yanzhang impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT jiyanliu impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients AT yanli impactofthoracicradiotherapyonfirstlinetreatmentoutcomesinessclcpatients |